
Itraconazole Capsules 100 mg

BOXED WARNING

Congestive Heart Failure, Cardiac Effects and Drug Interactions:

Itraconazole capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. If signs or symptoms of congestive heart failure occur during administration of itraconazole capsules, discontinue administration. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. (See CONTRAINDICATIONS, WARNINGS, PRECAUTIONS.


Drug Interactions, ADVERSE REACTIONS: Post-marketing Experience, and CLINICAL PHARMACOLOGY: Special Populations for more information.)

Drug Interactions: Coadministration of the following drugs are contraindicated with Itraconazole Capsules: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide,triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor. In addition, coadministration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors. Coadministration with venetoclax is contraindicated in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) during the dose initiation and ramp-up phase of venetoclax. See PRECAUTIONS: Drug Interactions Section for specific examples. Coadministration with itraconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia. See CONTRAINDICATIONS and WARNINGS Sections, and PRECAUTIONS: Drug Interactions Section for specific examples.

DESCRIPTION

Itraconazole, an azole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. It may be represented by the following structural formula and nomenclature:

CH₃



 $\label{eq:linear_state} \begin{array}{l} (\pm)-1-[(R^*)-sec-buty]]-4-[p-[4-[p-[((2R^*,4S^*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-\Delta^2 -1,2,4-triazolin-5-one mixture with (\pm)-1-[(R^*)-sec-butyl]-4-[p-[4-[p-[((2S^*,4R^*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-\Delta^2 -1,2,4-triazolin-5-one \end{array}$

or

(±)-1-[(RS)-sec-buty]]-4-[p-[4-[p-[((2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]- Δ^2 -1,2,4-triazolin-5-one

Itraconazole has a molecular formula of $C_{35}H_{38}Cl_2N_8O_4$ and a molecular weight of 705.64. It is a white or almost white powder. Freely soluble in methylene chloride, sparingly soluble in tetrahydrofuran, very slightly soluble in alcohol and practically insoluble in water. It has a pKa of 3.70 (based on extrapolation of values obtained from methanolic solutions) and a log (n-octanol/water) partition coefficient of 5.66 at pH 8.1.

Itraconazole capsules contain 100 mg of itraconazole coated on sugar spheres (composed of sucrose, maize starch and purified water). Inactive ingredients are hard gelatin capsule, hypromellose, poloxamer 188,ethanol absolute, methylene chloride, polyethylene glycol 20000, talc, colloidal silicon dioxide, SLS, titanium dioxide, FD&C blue 1,FD&C red 40,FD&C red 3 and white ink (containing: shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, titanium dioxide and potassium hydroxide).

FDA approved dissolution test specifications differ from USP

CLINICAL PHARMACOLOGY

Pharmacokinetics and Metabolism:

General Pharmacokinetic Characteristics

Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following oral administration. As a consequence of non-linear pharmacokinetics, itraconazole accumulates in plasma during multiple dosing. Steady-state concentrations are generally reached within about 15 days, with C_{max} values of 0.5 mcg/mL, 1.1 mcg/mL and 2.0 mcg/mL after oral administration of 100 mg once daily, 200 mg once daily and 200 mg b.i.d., respectively. The terminal half-life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing. Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within 7 to 14 days, depending on the dose and duration of treatment. Itraconazole mean total plasma clearance following intravenous administration is 278 mL/min. Itraconazole clearance decreases at higher doses due to saturable hepatic metabolism.

Absorption

Itraconazole is rapidly absorbed after oral administration. Peak plasma concentrations of itraconazole are reached within 2 to 5 hours following an oral capsule dose. The observed absolute oral bioavailability of itraconazole is about 55%.

The oral bioavailability of itraconazole is maximal when itraconazole capsules are taken immediately after a full meal. Absorption of itraconazole capsules is reduced in subjects with reduced gastric acidity, such as subjects taking medications known as gastric acid secretion suppressors (e.g., H₂-receptor antagonists, proton pump inhibitors) or subjects with achlorhydria caused by certain diseases. (See PRECAUTIONS: Drug Interactions.) Absorption of itraconazole under fasted conditions in these subjects is increased when itraconazole capsules are administered with an acidic beverage (such as a non-diet cola). When itraconazole capsules were administered as a single 200-mg dose under fasted conditions with non-diet cola after ranitidine pretreatment, a H₂ -receptor antagonist, itraconazole absorption was comparable to that observed when itraconazole capsules were administered solver on the itraconazole capsules were administered solver on the itraconazole absorption solver antagonist. Distinct of the table to that observed when itraconazole capsules were administered alone. (See PRECAUTIONS: Drug Interactions.)

Itraconazole exposure is lower with the Capsule formulation than with the Oral Solution when the same dose of drug is given. (See WARNINGS)

Distribution

Most of the itraconazole in plasma is bound to protein (99.8%), with albumin being the main binding component (99.6% for the hydroxy-metabolite). It has also a marked affinity for lipids. Only 0.2% of the itraconazole in plasma is present as free drug. Itraconazole is distributed in a large apparent volume in the body (>700 L), suggesting extensive distribution into tissues. Concentrations in lung, kidney, liver, bone, stomach, spleen and muscle were found to be two to three times higher than corresponding concentrations in plasma, and the uptake into keratinous tissues, skin in particular, up to four times higher. Concentrations in the cerebrospinal fluid are much lower than in plasma.

Metabolism

Itraconazole is extensively metabolized by the liver into a large number of metabolites. *In vitro* studies have shown that CYP3A4 is the major enzyme involved in the metabolism of itraconazole. The main metabolite is hydroxy-itraconazole, which has *in vitro* antifungal activity comparable to itraconazole; trough plasma concentrations of this metabolite are about twice those of itraconazole.

Excretion

Itraconazole is excreted mainly as inactive metabolites in urine (35%) and in feces (54%) within one week of an oral solution dose. Renal excretion of itraconazole and the active metabolite hydroxy-itraconazole account for less than 1% of an intravenous dose. Based on an oral radiolabeled dose, fecal excretion of unchanged drug ranges from 3% to 18% of the dose.

As re-distribution of itraconazole from keratinous tissues appears to be negligible, elimination of itraconazole from these tissues is related to epidermal regeneration. Contrary to plasma, the concentration in skin persists for 2 to 4 weeks after discontinuation of a 4-week treatment and in nail keratin – where itraconazole can be detected as early as 1 week after start of treatment – for at least six months after the end of a 3-month treatment period.

Special Populations:

Renal Impairment:

Limited data are available on the use of oral itraconazole in patients with renal impairment. A pharmacokinetic study using a single 200-mg oral dose of itraconazole was conducted in three groups of patients with renal impairment (uremia: n=7; hemodialysis: n=7; and continuous ambulatory peritoneal dialysis: n=5). In uremic subjects with a mean creatinine clearance of $13mL/min. \times 1.73m^2$, the exposure, based on AUC, was slightly reduced compared with normal population parameters. This study did not demonstrate any significant effect of hemodialysis or continuous ambulatory peritoneal dialysis on the pharmacokinetics of itraconazole (T_{max} , C_{max} , and AUC_{0-8h}). Plasma concentration-versus- time profiles showed wide intersubject variation in all three groups. After a single intravenous dose, the mean terminal half-lives of itraconazole in patients with mild (defined in this study as CrCl 50 to 79 mL/min), moderate (defined in this study as CrCl 20 to 49 mL/min), and severe renal impairment (defined in this study as CrCl <20 mL/min) were similar to that in healthy subjects (range of means 42 to 49 hours vs 48 hours in renally impaired patients and healthy subjects, respectively). Overall exposure to itraconazole, based on AUC, was decreased in patients with moderate and severe renal impairment by approximately 30% and 40%, respectively, as compared with subjects with normal renal function. Data are not available in renally impaired patients during long-term use of itraconazole. Dialysis has no effect on the halflife or clearance of itraconazole or hydroxy-itraconazole. (See PRECAUTIONS and DOSAGE AND ADMINISTRATION.)

Hepatic Impairment:

Itraconazole is predominantly metabolized in the liver. A pharmacokinetic study was conducted in 6 healthy and 12 cirrhotic subjects who were administered a single 100-mg dose of itraconazole as capsule. A statistically significant reduction in mean C_{max} (47%) and a twofold increase in the elimination half-life (37 ± 17 hours vs. 16 ± 5 hours) of itraconazole were noted in cirrhotic subjects compared with healthy subjects. However, overall exposure to itraconazole, based on AUC, was similar in cirrhotic patients and in healthy subjects. Data are not available in cirrhotic patients during long-term use of itraconazole. (See CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions and DOSAGE AND ADMINISTRATION.)

Decreased Cardiac Contractility:

When itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was documented. In a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular ejection fraction were observed using gated SPECT imaging; these resolved before the next infusion, 12 hours later. If signs or symptoms of congestive heart failure appear during administration of itraconazole capsules, itraconazole capsules should be discontinued. (See BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS: Drug Interactions and ADVERSE REACTIONS: Post-marketing Experience for more information.)

MICROBIOLOGY

Mechanism of Action:

In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.

Antimicrobial Activity:

Itraconazole exhibits in vitro activity against *Blastomyces dermatitidis, Histoplasma capsulatum,Histoplasma duboisii, Aspergillus flavus, Aspergillus fumigatus, and Trichophyton* species (See INDICATIONS AND USAGE: Description of Clinical Studies).

Susceptibility Testing Methods:

For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

Resistance:

Isolates from several fungal species with decreased susceptibility to itraconazole have been isolated in vitro and from patients receiving prolonged therapy.

Itraconazole is not active against *Zygomycetes* (e.g., *Rhizopus* spp., *Rhizomucor* spp., *Mucor* spp. and *Absidia* spp.), *Fusarium* spp., *Scedosporium* spp. and *Scopulariopsis* spp.

Cross-resistance:

Several in vitro studies have reported that some fungal clinical isolates with reduced susceptibility to one azole antifungal agent may also be less susceptible to other azole derivatives. The finding of cross-resistance is dependent on a number of factors, including the species evaluated, its clinical history, the particular azole compounds compared, and the type of susceptibility test that is performed.

Studies (both in vitro and in vivo) suggest that the activity of amphotericin B may be suppressed by prior azole antifungal therapy. As with other azoles, itraconazole inhibits the ¹⁴C-demethylation step in the synthesis of ergosterol, a cell wall component of fungi. Ergosterol is the active site for amphotericin B. In one study the antifungal activity of amphotericin B against *Aspergillus fumigatus* infections in mice was inhibited by ketoconazole therapy. The clinical significance of test results obtained in this study is unknown.

INDICATIONS & USAGE

Itraconazole capsules are indicated for the treatment of the following fungal infections in <u>immunocompromised and non-immunocompromised</u> patients:

1. Blastomycosis, pulmonary and extrapulmonary

2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal

histoplasmosis, and

3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are

refractory to amphotericin B therapy.

Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology,serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly.

Itraconazole capsules are also indicated for the treatment of the following fungal infections in $\underline{non-immunocompromised}$

patients:

1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and

2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium).

Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis.(See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS: Post-marketing Experience for more information.)

Description of Clinical Studies:

Blastomycosis:

Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of irraconazole for the treatment of blastomycosis compared with the natural history of untreated cases.

Histoplasmosis:

Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV-infected patients). The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared with the natural history of untreated cases.

Histoplasmosis in HIV-infected patients:

Data from a small number of HIV-infected patients suggested that the response rate of histoplasmosis in HIV-infected patients is similar to that of non-HIV-infected patients. The clinical course of histoplasmosis in HIV-infected patients is more severe and usually requires maintenance therapy to prevent relapse.

Aspergillosis:

Analyses were conducted on data from an open-label, "single-patient-use" protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open-label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy.

Onychomycosis of the toenail:

Analyses were conducted on data from three double-blind, placebo-controlled studies (N=214 total;110 given itraconazole capsules) in which patients with onychomycosis of the toenails received 200 mg of itraconazole capsules once daily for 12 consecutive weeks. Results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 54% of patients. Thirty-five percent (35%) of patients were considered an overall success(mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clear or minimal nail deformity). The mean time to overall success was approximately 10 months. Twenty-one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of KOH or culture from negative to positive).

Onychomycosis of the fingernail:

Analyses were conducted on data from a double-blind, placebo-controlled study (N=73 total; 37 given itraconazole capsules) in which patients with onychomycosis of the fingernails received a 1-week course of 200 mg of itraconazole capsules b.i.d., followed by a 3-week period without itraconazole, which was followed by a second 1-week course of 200 mg of itraconazole capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty-six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. The mean time to overall success was approximately 5 months. None of the patients who achieved overall success relapsed.

CONTRAINDICATIONS

Congestive Heart Failure:

Itraconazole capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. (See BOXED WARNING, WARNINGS, PRECAUTIONS: Drug Interactions-Calcium Channel Blockers, ADVERSE REACTIONS: Post-marketing Experience, and CLINICAL PHARMACOLOGY: Special Populations.)

Drug Interactions:

Coadministration of a number of CYP3A4 substrates are contraindicated with itraconazole capsules. Plasma concentrations increase for the following drugs: methadone, disopyramide, dofetilide, dronedarone, guinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor. In addition, coadministration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and coadministration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors.(See PRECAUTIONS: Drug Interactions Section for specific examples.) This increase in drug concentrations caused by coadministration with itraconazole may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. Specific examples are listed in PRECAUTIONS: Drug Interactions.

Coadministration with venetoclax is contraindicated in patients with CLL/SLL during the dose initiation and ramp-up phase of venetoclax due to the potential for an increased risk of tumor lysis syndrome.

Itraconazole capsules should not be administered for the treatment of onychomycosis to pregnant patients or to women contemplating pregnancy.

Itraconazole capsules are contraindicated for patients who have shown hypersensitivity to itraconazole. There is limited information regarding cross-hypersensitivity between itraconazole and other azole antifungal agents. Caution should be used when prescribing itraconazole capsules to patients with hypersensitivity to other azoles.

WARNINGS

Hepatic Effects:

Itraconazole capsules has been associated with rare cases of serious hepatotoxicity, including liver failure and death. Some of these cases had neither pre-existing liver disease nor a serious underlying medical condition, and some of these cases developed within the first week of treatment. If clinical signs or symptoms develop that are consistent with liver disease, treatment should be discontinued and liver function testing performed. Continued itraconazole capsules use or reinstitution of treatment with itraconazole capsules are strongly discouraged unless there is a serious or life-threatening situation where the expected benefit exceeds the risk. (See PRECAUTIONS: Information for Patients and ADVERSE REACTIONS.)

Cardiac Dysrhythmias:

Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using drugs such as cisapride, pimozide, methadone, or quinidine concomitantly with itraconazole capsules and/or other CYP3A4 inhibitors. Concomitant administration of these drugs with itraconazole capsules are contraindicated. (See BOXED WARNING, CONTRAINDICATIONS, and PRECAUTIONS: Drug Interactions.)

Cardiac Disease:

Itraconazole capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. Itraconazole capsules should not be used for other indications in patients with evidence of ventricular dysfunction unless the benefit clearly outweighs the risk.

For patients with risk factors for congestive heart failure, physicians should carefully review the risks and benefits of itraconazole capsules therapy. These risk factors include cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disease; and renal failure and other edematous disorders. Such patients should be informed of the signs and symptoms of CHF, should be treated with caution, and should be monitored for signs and symptoms of CHF during treatment. If signs or symptoms of CHF appear during administration of itraconazole capsules, discontinue administration.

Itraconazole has been shown to have a negative inotropic effect. When itraconazole was administered intravenously to anesthetized dogs, a dose-related negative inotropic effect was documented. In a healthy volunteer study of itraconazole intravenous infusion, transient, asymptomatic decreases in left ventricular ejection fraction were observed using gated SPECT imaging; these resolved before the next infusion, 12 hours later.

Itraconazole capsules has been associated with reports of congestive heart failure. In post-marketing experience, heart failure was more frequently reported in patients receiving a total daily dose of 400 mg although there were also cases reported among those receiving lower total daily doses.

Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolism of calcium channel blockers. Therefore, caution should be used when co-administering itraconazole and calcium channel blockers due to an increased risk of CHF. Concomitant administration of itraconazole capsules and felodipine or nisoldipine is contraindicated.

Cases of CHF, peripheral edema, and pulmonary edema have been reported in the postmarketing period among patients being treated for onychomycosis and/or systemic fungal infections. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions, and ADVERSE REACTIONS: Post-marketing Experience for more information.)

Interaction potential:

Itraconazole capsules has a potential for clinically important drug interactions. Coadministration of specific drugs with itraconazole may result in changes in efficacy of itraconazole and/or the coadministered drug, life-threatening effects and/or sudden death. Drugs that are contraindicated, not recommended or recommended for use with caution in combination with itraconazole are listed in PRECAUTIONS: Drug Interactions.

Interchangeability:

Itraconazole capsules and itraconazole oral solution should not be used interchangeably. This is because drug exposure is greater with the Oral Solution than with the Capsules when the same dose of drug is given. In addition, the topical effects of mucosal exposure may be different between the two formulations. Only the Oral Solution has been demonstrated effective for oral and/or esophageal candidiasis.

PRECAUTIONS

General:

Itraconazole capsules should be administered after a full meal. (See CLINICAL PHARMACOLOGY: Pharmacokinetics and Metabolism).

Under fasted conditions, itraconazole absorption was decreased in the presence of decreased gastric acidity. The absorption of itraconazole may be decreased with the concomitant administration of antacids or gastric acid secretion suppressors. Studies conducted under fasted conditions demonstrated that administration with 8 ounces of a non-diet cola beverage resulted in increased absorption of itraconazole in AIDS patients with relative or absolute achlorhydria. This increase relative to the effects of a full meal is unknown. (See CLINICAL PHARMACOLOGY: Pharmacokinetics and Metabolism).

Hepatotoxicity:

Rare cases of serious hepatotoxicity have been observed with itraconazole capsules treatment, including some cases within the first week. It is recommended that liver function monitoring be considered in all patients receiving itraconazole capsules. Treatment should be stopped immediately and liver function testing should be conducted in patients who develop signs and symptoms suggestive of liver dysfunction.

Neuropathy:

If neuropathy occurs that may be attributable to itraconazole capsules, the treatment should be discontinued.

Immunocompromised Patients:

In some immunocompromised patients (e.g., neutropenic, AIDS or organ transplant patients), the oral bioavailability of itraconazole capsules may be decreased. Therefore, the dose should be adjusted based on the clinical response in these patients.

Cystic Fibrosis:

If a cystic fibrosis patient does not respond to itraconazole capsules, consideration

should be given to switching to alternative therapy. For more information concerning the use of itraconazole in cystic fibrosis patients see the prescribing information for itraconazole oral solution.

Hearing Loss:

Transient or permanent hearing loss has been reported in patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated (See BOXED WARNING: Drug Interactions, CONTRAINDICATIONS: Drug Interactions and PRECAUTIONS: Drug Interactions). The hearing loss usually resolves when treatment is stopped, but can persist in some patients.

Information for Patients:

• The topical effects of mucosal exposure may be different between the itraconazole capsules and oral solution. Only the Oral Solution has been demonstrated effective for oral and/or esophageal candidiasis. Itraconazole capsules should not be used interchangeably with itraconazole oral solution.

 \cdot Instruct patients to take itraconazole capsules with a full meal. Itraconazole capsules must be swallowed whole.

 Instruct patients about the signs and symptoms of congestive heart failure, and if these signs or symptoms occur during itraconazole capsules administration, they should discontinue itraconazole capsules and contact their healthcare provider immediately.

 Instruct patients to stop itraconazole capsules treatment immediately and contact their healthcare provider if any signs and symptoms suggestive of liver dysfunction develop. Such signs and symptoms may include unusual fatigue, anorexia, nausea and/or vomiting, jaundice, dark urine, or pale stools.

 \cdot Instruct patients to contact their physician before taking any concomitant medications with itraconazole to ensure there are no potential drug interactions.

• Instruct patients that hearing loss can occur with the use of itraconazole. The hearing loss usually resolves when treatment is stopped, but can persist in some patients. Advise patients to discontinue therapy and inform their physicians if any hearing loss symptoms occur.

 \cdot Instruct patients that dizziness or blurred/double vision can sometimes occur with itraconazole. Advise patients that if they experience these events, they should not drive or use machines.

Drug Interactions

Effect of Itraconazole on Other Drugs

Itraconazole and its major metabolite, hydroxy-itraconazole, are potent CYP3A4 inhibitors. Itraconazole is an inhibitor of the drug transporters P-glycoprotein and breast cancer resistance protein (BCRP). Consequently, itraconazole has the potential to interact with many concomitant drugs resulting in either increased or sometimes decreased concentrations of the concomitant drugs. Increased concentrations may increase the risk of adverse reactions associated with the concomitant drug which can be severe or life-threatening in some cases (e.g., QT prolongation, *Torsade de Pointes*, respiratory depression, hepatic adverse reactions, hypersensitivity reactions, myelosuppression, hypotension, seizures, angioedema, atrial fibrillation, bradycardia, priapism). Reduced concentrations of concomitant drugs may reduce their efficacy. Table 1 lists examples of drugs that may have their concentrations affected by itraconazole, but is not a comprehensive list. Refer to the approved product labeling to become familiar with the interaction pathways, risk potential, and specific actions to be taken with regards to each concomitant drug prior to initiating therapy with itraconazole.

Although many of the clinical drug interactions in Table 1 are based on information with a similar azole antifungal, ketoconazole, these interactions are expected to occur with itraconazole.

Table 1 Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations		
Concomitant Drug Within Class	Prevention or Management	
Drug Interactions with Itraconazole that Increase Concomit	ant Drug Concentrations and May Increase Risk of Adverse Reactions	
Associated with the Concomitant Drug		
Alpha Blockers		
Alfuzosin	Not recommended during and 2 weeks after	
Silodosin	itraconazole treatment.	
Tamsulosin		
Analgesics		
Methadone	Contraindicated during and 2 weeks after	
	itraconazole treatment.	
Fentanyl	Not recommended during and 2 weeks after	
	itraconazole treatment.	
Alfentanil		
Buprenorphine (IV and sublingual)	Monitor for adverse reactions. Concomitant drug dose reduction may be	
Oxycodone ^a	necessary.	
Sufentanil		

Antiarrhythmics	
Disopyramide	
Dofetilide	Contraindicated during and 2 weeks after
Dronedarone	itraconazole treatment.
Ouinidinea	
	Monitor for adverse reactions. Concomitant drug dose reduction may be
Digoxin ^a	necessary.
Antibacterials	
Bedaguiline ^b	Concomitant itraconazole not recommended for more than 2 weeks at any time
	during bedaquiline treatment.
Rifabutin	Not recommended 2 weeks before, during, and 2 weeks after itraconazole
	treatment. See also Table 2.
Clarithromycin	Monitor for adverse reactions. Concomitant drug dose reduction may be
	necessary. See also Table 2.
Trimetrexate	Monitor for adverse reactions. Concomitant drug dose reduction may be
	necessary.
Anticoagulants and Antiplatelets	
Ticagrelor	Contraindicated during and 2 weeks after itraconazole treatment.
Apixaban	Net was was and during and 2 weaks often itwass was als tweather at
Rivaroxaban	Not recommended during and 2 weeks after itraconazole treatment.
Vorapaxar	
Cilostazol Dabigatran	Monitor for adverse reactions. Concomitant drug dose reduction may be
Warfarin	necessary.
Anticonvulsants	
Anticonvulsants	Not recommended 2 weeks before, during, and 2 weeks after itraconazole
Carbamazepine	treatment. See also Table 2.
Antidiabetic Drugs	
Repaglinide ^a	Monitor for adverse reactions. Concomitant drug dose reduction may be
Saxagliptin	necessary.
Antihelminthics, Antifungals and Antiprotozoals	······································
Isavuconazonium	Contraindicated during and 2 weeks after itraconazole treatment.
	Monitor for adverse reactions. Concomitant drug dose reduction may be
Praziquantel	necessary.
Artemether-lumefantrine	Monitor for adverse reactions.
Quinine ^a	
Antimigraine Drugs	
Ergot alkaloids (e.g., dihydroergotamine,	Contraindicated during and 2 weeks after itraconazole treatment. dose
ergotamine)	reduction may be necessary.
Eletriptan	Monitor for adverse reactions. Concomitant drug dose reduction may be
	necessary
Antineoplastics	
Irinotecan	Contraindicated during and 2 weeks after itraconazole treatment.
	Contraindicated during the dose initiation and ramp-up phase in patients with
Venetoclax	CLL/SLL. Refer to the venetoclax prescribing information for dosing and safety
	monitoring instructions.
Axitinib Bosutinib	
Cabazitaxel	
Cabozantinib	
Ceritinib	
Cobimetiniba	
Crizotinib	
Dabrafenib	
Dasatinib	
Docetaxel	Not recommended during and 2 weeks after itraconazole treatment.
Ibrutinib	5
Lapatinib	
Nilotinib	
Olaparib ^a	
Pazopanib	
Trabectedin	
Trabectedin Trastuzumab-emtansine	
Trabectedin	
Trabectedin Trastuzumab-emtansine Vinca alkaloids	Refer to the talazoparib prescribing information for dosing instructions if
Trabectedin Trastuzumab-emtansine	concomitant use cannot be avoided.
Trabectedin Trastuzumab-emtansine Vinca alkaloids	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib	concomitant use cannot be avoided.
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided.
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided. Monitor for adverse reactions. Concomitant drug dose reduction may be
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib Panobinostat	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided.
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib Panobinostat Ponatinib	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided. Monitor for adverse reactions. Concomitant drug dose reduction may be
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib Panobinostat Ponatinib Ruxolitinib	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided. Monitor for adverse reactions. Concomitant drug dose reduction may be
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib Panobinostat Ponatinib Ruxolitinib Sonidegib	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided. Monitor for adverse reactions. Concomitant drug dose reduction may be
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib Panobinostat Ponatinib Ruxolitinib	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided. Monitor for adverse reactions. Concomitant drug dose reduction may be
Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib Panobinostat Ponatinib Ruxolitinib Sonidegib Tretinoin (oral)	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided. Monitor for adverse reactions. Concomitant drug dose reduction may be
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib Panobinostat Ponatinib Ruxolitinib Sonidegib Tretinoin (oral) Vandetanib ^a	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided. Monitor for adverse reactions. Concomitant drug dose reduction may be
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib Panobinostat Ponatinib Ruxolitinib Sonidegib Tretinoin (oral) Vandetanib ^a Imatinib Ixabepilone Antipsychotics, Anxiolytics and Hypnotics	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided. Monitor for adverse reactions. Concomitant drug dose reduction may be
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib Panobinostat Ponatinib Ruxolitinib Sonidegib Tretinoin (oral) Vandetanib ^a Imatinib Ixabepilone Antipsychotics, Anxiolytics and Hypnotics	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided. Monitor for adverse reactions. Concomitant drug dose reduction may be
Trabectedin Trastuzumab-emtansine Vinca alkaloids Talazoparib ^a Glasdegib Bortezomib Brentuximab-vedotin Busulfan ^a Erlotinib Gefitinib ^a Idelalisib Nintedanib Panobinostat Ponatinib Ruxolitinib Sonidegib Tretinoin (oral) Vandetanib ^a Imatinib Inatinib	concomitant use cannot be avoided. Refer to the glasdegib prescribing information for safety monitoring if concomitant use cannot be avoided. Monitor for adverse reactions. Concomitant drug dose reduction may be

Buspirone ^a	
Cariprazine	
Diazepam ^a	
Haloperidola	Monitor for adverse reactions. Concomitant drug dose reduction may be
Midazolam (IV) ^a	necessary.
Quetiapine	
Ramelteon	
Risperidone ^a	
Suvorexant	
Zopiclone ^a	Monitor for adverse reactions. Concomitant drug dose reduction may be necessary.
Lurasidone	
Midazolam (oral) ^a	Contraindicated during and 2 weeks after itraconazole treatment.
Pimozide	contraindicated during and 2 weeks after itraconazole treatment.
Triazolama	
Antivirals	
Daclatas vir ndinavir ^a	Monitor for adverse reactions. Concomitant drug dose reduction may be
Maraviroc	necessary. For indinavir, see also Table 2.
Cobicistat	
Elvitegravir (ritonavir-boosted)	
Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir	Monitor for adverse reactions. See also Table 2.
Ritonavir	
Saquinavir (unboosted) ^a	
Elbasvir/grazoprevir	Not recommended during and 2 weeks after itraconazole treatment.
Glecaprevir/pibrentasvir Fenofovir disoproxil fumarate	Monitor for adverse reactions. Monitor for adverse reactions.
Beta Blockers	איטווגטו זטו מעיכו זכ וכמנגוטווג.
	Monitor for adverse reactions. Concomitant drug dose reduction may be
Nadolola	necessary.
Calcium Channel Blockers	
Felodipine ^a	Contraindicated during and 2 weeks after itraconazole treatment.
Nisoldipine	
Diltiazem Other dihydropyridines	Monitor for adverse reactions. Concomitant drug dose reduction may be
Verapamil	necessary. For diltiazem, see also Table 2.
Cardiovascular Drugs, Miscellaneous	
Ivabradine	Contraindicated during and 2 weeks after itraconately treatment
Ranolazine	Contraindicated during and 2 weeks after itraconazole treatment.
Aliskiren ^a	
Riociguat	Not recommended during and 2 weeks after itraconazole treatment. For
Sildenafil (for pulmonary hypertension) Tadalafil (for pulmonary hypertension)	sildenafil and tadalafil, see also Urologic Drugs below.
Bosentan	Monitor for adverse reactions. Concomitant drug dose reduction may be
Guanfacine	necessary.
Contraceptives*	necessary.
Dienogest	Monitor for adverse reactions.
Ulipristal	
Diuretics	
Eplerenone Gastrointestinal Drugs	Contraindicated during and 2 weeks after itraconazole treatment.
Cisapride	
Naloxegol	Contraindicated during and 2 weeks after itraconazole treatment.
Aprepitant	Monitor for adverse reactions. Concomitant drug dose reduction may be
Loperamide ^a	necessary.
Netupitant	Monitor for adverse reactions.
Immunosuppressants	
Everolimus Sirolimus	Not recommended during and 2 weeks after itraconazole treatment.
Temsirolimus (IV)	איטר דפנטרוודופוועפע עעדווש מווע ב שפכאס מונפו ונו מנטוומבטופ נו פמנווופוונ.
Budesonide (inhalation) ^a	
Budesonide (non-inhalation)	
Ciclesonide (inhalation)	
Cyclosporine (IV) ^a	
Cyclosporine (non-IV)	Monitor for adverse reactions. Concomitant drug dose reduction may be
Dexamethasone ^a	necessary.
Fluticasone (inhalation) ^a Fluticasone (nasal)	
Fluticasone (nasal) Methylprednisolone ^a	
Tacrolimus (IV) ^a	
Tacrolimus (oral)	
Lipid-Lowering Drugs	
Lomitapide	
Lovastatin ^a	Contraindicated during and 2 weeks after itraconazole treatment.
Simvastatin ^a	Monitor for drug advorce reactions. Concomitent drug dass reduction merche
Atorvastatin ^a	Monitor for drug adverse reactions. Concomitant drug dose reduction may be necessary.
Respiratory Drugs	processury.
Salmeterol	Not recommended during and 2 weeks after itraconazole treatment.
SSRIs, Tricyclics and Related Antidepressants	
Venlafaxine	Monitor for adverse reactions. Concomitant drug dose reduction may be
	necessary.
Urologic Drugs	Contraindicated during and 2 weeks after itraconately treatment
Avanafil	Contraindicated during and 2 weeks after itraconazole treatment. Patients with moderate to severe renal or hepatic impairment: Contraindicated
	Contraindicated during and 2 weeks after itraconazole treatment. Patients with moderate to severe renal or hepatic impairment: Contraindicated during and 2 weeks after itraconazole treatment.

	reduction may be necessary.
	Patients with severe renal or moderate to severe hepatic impairment:
Solifenacin	Contraindicated during and 2 weeks after itraconazole treatment.
Somenacin	Other patients: Monitor for adverse reactions. Concomitant drug dose
	reduction may be necessary.
Darifenacin Vardenafil	Not recommended during and 2 weeks after itraconazole treatment.
Dutasteride	
Oxybutynin ^a	
Sildenafil (for erectile dysfunction)	Monitor for adverse reactions. Concomitant drug dose reduction may be
Tadalafil (for erectile dysfunction and benign prostatic hyperplasia)	necessary. For sildenafil and tadalafil, see also Cardiovascular Drugs above.
Tolterodine	
Miscellaneous Drugs and Other Substances	
	Patients with renal or hepatic impairment:
Calabiaina	Contraindicated during and 2 weeks after itraconazole treatment.
Colchicine	Other patients: Not recommended during and 2 weeks after itraconazole
	treatment.
	CYP2D6 EMs ^c taking a strong or moderate
	CYP2D6 inhibitor, CYP2D6 IMs ^c , or CYP2D6
Eliglustat	PMs ^c : Contraindicated during and 2 weeks after itraconazole treatment.
Eligiustat	
	CYP2D6 EMs ^c not taking a strong or moderate CYP2D6 inhibitor: Monitor for
	adverse reactions. Eliglustat dose reduction may be necessary.
Lumacaftor/Ivacaftor	Not recommended 2 weeks before, during, and 2 weeks after itraconazole
	treatment.
Alitretinoin (oral)	
Cabergoline	
Cannabinoids	Monitor for adverse reactions. Concomitant drug dose reduction may be
Cinacalcet	necessary.
Galantamine	
Ivacaftor Vasopressin Receptor Antagonists	
Conivaptan	
Tolvaptan	Not recommended during and 2 weeks after itraconazole treatment.
	Drug Concentrations and May Reduce Efficacy of the Concomitant Drug
Antineoplastics	Drug concentrations and may neduce Efficacy of the concomitant Drug
Regorafenib	Not recommended during and 2 weeks after itraconazole treatment.
Gastrointestinal Drugs	
Saccharomyces boulardii	Not recommended during and 2 weeks after itraconazole treatment.
Nonsteroidal Anti-Inflammatory Drugs	
Meloxicam ^a	Concomitant drug dose increase may be necessary.

*CYP3A4 inhibitors (including itraconazole) may increase systemic contraceptive hormone concentrations.

^a Based on clinical drug interaction information with itraconazole.

^b Based on 400 mg bedaquiline once daily for 2 weeks.

^c EMs: extensive metabolizers; IMs: intermediate metabolizers, PMs: poor metabolizers

Effect of Other Drugs on Itraconazole

Itraconazole is mainly metabolized through CYP3A4. Other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. Some concomitant drugs have the potential to interact with itraconazole resulting in either increased or sometimes decreased concentrations of itraconazole. Increased concentrations may increase the risk of adverse reactions associated with itraconazole.

Decreased concentrations may reduce itraconazole efficacy.

Table 2 lists examples of drugs that may affect itraconazole concentrations, but is not a comprehensive list. Refer to the approved product labeling to become familiar with the interaction pathways, risk potential and specific actions to be taken with regards to each concomitant drug prior to initiating therapy with itraconazole. Although many of the clinical drug interactions in Table 2 are based on information with a

Although many of the clinical drug interactions in Table 2 are based on information with a similar azole antifungal, ketoconazole, these interactions are expected to occur with itraconazole.

Table 2. Drug Interactions with Other Drugs that Affect Itraconazole Concentrations	
Concomitant Drug Within Class	Prevention or Management
	crease Itraconazole Concentrations and May Increase Risk of
Adverse Reactions Associated with Itracon	azole
Antibacterials	
Ciprofloxacin ^a	Monitor for adverse reactions. Itraconazole dose reduction may be
Erythromycin ^a	necessary.
Clarithromycin ^a	
Antineoplastics	
I delalis ib	Monitor for adverse reactions. Itraconazole dose reduction may be
	necessary. See also Table 1.
Antivirals	
Cobicistat	Monitor for adverse reactions. Itraconazole dose reduction may be
Darunavir (ritonavir-boosted)	necessary. For, cobicistat, elvitegravir,indinavir,ombitasvir/paritaprevir/
Elvitegravir (ritonavir-boosted) Fosamprenavir	ritonavir with or without dasabuvir ,ritonavir, and saquinavir, see also
(ritonavir-boosted) Indinavir ^a	Table 1.
Ombitasvir/Paritaprevir/Ritonavir with or without	
Dasabuvir Ritonavir Saguinavir	

Calcium Channel Blockers		
Diltiazem	Monitor for adverse reactions. Itraconazole dose reduction may be	
	necessary. See also Table 1.	
Drug Interactions with Other Drugs that De	crease Itraconazole Concentrations and May Reduce Efficacy	
of Itraconazole		
Antibacterials		
Isoniazid	Not recommended 2 weeks before and during itraconazole treatment.	
Rifampicin ^a		
Rifabutin ^a	Not recommended 2 weeks before, during, and 2 weeks after	
	itraconazole treatment. See also Table 1.	
Anticonvulsants		
Phenobarbital	Not recommended 2 weeks before and during itraconazole treatment.	
Phenytoin ^a		
Carbamazepine	Not recommended 2 weeks before, during, and 2 weeks after	
	itraconazole treatment. See also Table 1.	
Antivirals		
Efavirenz ^a	Not recommended 2 weeks before and during itraconazole treatment.	
Nevirapine ^a		
Gastrointestinal Drugs		
Drugs that reduce gastric acidity e.g. acid	Use with caution. Administer acid neutralizing medicines at least 2	
neutralizing medicines such as aluminum	hours before or 2 hours after the intake of itraconazole capsules	
hydroxide, or acid secretion suppressors such as		
H ₂ - receptor antagonists and proton pump		
inhibitors.		
Miscellaneous Drugs and Other Substances		
Lumacaftor/Ivacaftor	Not recommended 2 weeks before, during, and 2 weeks after	
	itraconazole treatment.	

^aBased on clinical drug interaction information with itraconazole.

Pediatric Population

Interaction studies have only been performed in adults.

Carcinogenesis & Mutagenesis & Impairment of Fertility:

Itraconazole showed no evidence of carcinogenicity potential in mice treated orally for 23 months at dosage levels up to 80 mg/kg/day(approximately 10 times the maximum recommended human dose [MRHD]). Male rats treated with 25 mg/kg/day (3.1 times the MRHD) had a slightly increased incidence of soft tissue sarcoma. These sarcomas may have been a consequence of hypercholesterolemia, which is a response of rats, but not dogs or humans, to chronic itraconazole administration. Female rats treated with 50 mg/kg/day (6.25 times the MRHD) had an increased incidence of squamous cell carcinoma of the lung (2/50) as compared to the untreated group. Although the occurrence of squamous cell carcinoma in the lung is extremely uncommon in untreated rats, the increase in this study was not statistically significant. Itraconazole produced no mutagenic effects when assayed in DNA repair test (unscheduled DNA synthesis) in primary rat hepatocytes, in Ames tests with Salmonella typhimurium (6 strains) and Escherichia coli, in the mouse lymphoma gene mutation tests, in a sex-linked recessive lethal mutation (Drosophila melanogaster) test, in

male and female mice, and in micronucleus tests in mice and rats. Itraconazole did not affect the fertility of male or female rats treated orally with dosage levels of up to 40 mg/kg/day (5 times the MRHD), even though parental toxicity was present at this dosage level. More severe signs of parental toxicity, including death, were present in the next higher dosage level, 160 mg/kg/day (20 times the MRHD).

C3H/10T¹/₂ C18 mouse embryo fibroblasts cells, in a dominant lethal mutation test in

Pregnancy: Teratogenic effects :

Itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity, and teratogenicity in rats at dosage levels of approximately 40 to 160 mg/kg/day (5 to 20 times the MRHD), and in mice at dosage levels of approximately 80 mg/kg/day (10 times the MRHD). Itraconazole has been shown to cross the placenta in a rat model. In rats, the teratogenicity consisted of major skeletal defects; in mice, it consisted of encephaloceles and/or macroglossia.

There are no studies in pregnant women. Itraconazole capsules should be used for the treatment of systemic fungal infections in pregnancy only if the benefit outweighs the potential risk.

Itraconazole capsules should not be administered for the treatment of onychomycosis to pregnant patients or to women contemplating pregnancy. Itraconazole capsules should not be administered to women of childbearing potential for the treatment of onychomycosis unless they are using effective measures to prevent pregnancy and they begin therapy on the second or third day following the onset of menses. Highly effective contraception should be continued throughout itraconazole capsules therapy and for 2 months following the end of treatment.

During post-marketing experience, cases of congenital abnormalities have been reported. (See ADVERSE REACTIONS: Post-marketing Experience.)

Nursing Mothers:

Itraconazole is excreted in human milk; therefore, the expected benefits of itraconazole capsules therapy for the mother should be weighed against the potential risk from exposure of itraconazole to the infant. The U.S. Public Health Service Centers for Disease Control and Prevention advises HIV-infected women not to breast-feed to avoid potential transmission of HIV to uninfected infants.

Pediatric Use:

The efficacy and safety of itraconazole capsules have not been established in pediatric patients.

The long-term effects of itraconazole on bone growth in children are unknown. In three toxicology studies using rats, itraconazole induced bone defects at dosage levels as low as 20 mg/kg/day (2.5 times the MRHD). The induced defects included reduced bone plate activity, thinning of the zona compacta of the large bones, and increased bone fragility. At a dosage level of 80 mg/kg/day (10 times the MRHD) over 1 year or 160 mg/kg/day (20 times the MRHD) for 6 months, itraconazole induced small tooth pulp with hypocellular appearance in some rats.

Geriatric Use:

Clinical studies of itraconazole capsules did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. It is advised to use itraconazole capsules in these patients only if it is determined that the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Transient or permanent hearing loss has been reported in elderly patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated (See BOXED WARNING: Drug Interactions, CONTRAINDICATIONS:

Drug Interactions and PRECAUTIONS: Drug Interactions).

HIV-Infected Patients:

Because hypochlorhydria has been reported in HIV-infected individuals, the absorption of itraconazole in these patients may be decreased.

Renal Impairment:

Limited data are available on the use of oral itraconazole in patients with renal impairment. The exposure of itraconazole may be lower in some patients with renal impairment. Caution should be exercised when itraconazole is administered in this patient population and dose adjustment may be needed. (See CLINICAL PHARMACOLOGY: Special Populations and DOSAGE AND ADMINISTRATION.)

Hepatic Impairment:

Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population. It is recommended that patients with impaired hepatic function be carefully monitored when taking itraconazole capsules. It is recommended that the prolonged elimination half-life of itraconazole observed in the single oral dose clinical trial with itraconazole capsules in cirrhotic patients be considered when deciding to initiate therapy with other medications metabolized by CYP3A4.

In patients with elevated or abnormal liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment with itraconazole capsules is strongly discouraged unless there is a serious or life-threatening situation where the expected benefit exceeds the risk. It is recommended that liver function monitoring be done in patients with pre-existing hepatic function abnormalities or those who have experienced liver toxicity with other medications. (See CLINICAL PHARMACOLOGY: Special Populations and DOSAGE AND ADMINISTRATION.)

ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Itraconazole capsules has been associated with rare cases of serious hepatotoxicity, including liver failure and death. Some of these cases had neither pre-existing liver disease nor a serious underlying medical condition. If clinical signs or symptoms develop that are consistent with liver disease, treatment should be discontinued and liver function testing performed. The risks and benefits of itraconazole capsules use should be reassessed. (See WARNINGS: Hepatic Effects and PRECAUTIONS: Hepatotoxicity and Information for Patients.)

Adverse Events in the Treatment of Systemic Fungal Infections

Adverse event data were derived from 602 patients treated for systemic fungal disease in U.S. clinical trials who were immunocompromised or receiving multiple concomitant medications. Treatment was discontinued in 10.5% of patients due to adverse events. The median duration before discontinuation of therapy was 81 days (range: 2 to 776 days). The table lists adverse events reported by at least 1% of patients.

Table 3:Clinical Trials of Systemic Fungal Infections : Adverse Events Occurring with an Incidence of Greater than or Equal to 1%

Body System/Adverse Event	Incidence (%) (N=602)
Gastrointestinal	
Nausea	11
Vomiting	5

Diarrhea	3
Abdominal Pain	2
Anorexia	1
Body as a Whole	
Edema	4
Fatigue	3
Fever	3
Malaise	1
Skin and Appendages	
Rash*	9
Pruritus	3
Central/Peripheral Nervous System	
Headache	4
Dizziness	2
Psychiatric	
Libido Decreased	1
Somnolence	1
Cardiovascular	
Hypertension	3
Metabolic/Nutritional	
Hypokalemia	2
Urinary System	
Albuminuria	1
Liver and Biliary System	
Hepatic Function Abnormal	3
Reproductive System,Male	
Impotence	1

*Rash tends to occur more frequently in immunocompromised patients receiving immunosuppressive medications.

Adverse events infrequently reported in all studies included constipation, gastritis, depression, insomnia, tinnitus, menstrual disorder, adrenal insufficiency, gynecomastia, and male breast pain.

Adverse Events Reported in Toenail Onychomycosis Clinical Trials

Patients in these trials were on a continuous dosing regimen of 200 mg once daily for 12 consecutive weeks.

The following adverse events led to temporary or permanent discontinuation of therapy.

Table 4:Clinical Trials of Onychomycosis of the Toenail: Adverse Events Leading to Temporary or Permanent Discontinuation of Therapy

Adverse Event	Incidence (%) Itraconazole (N=112)
Elevated Liver Enzymes (greater than twice the upper limit of normal)	4
Gastrointestinal Disorders	4
Rash	3
Hypertension	2
Orthostatic Hypotension	1
Headache	1
Malaise	1
Myalgia	1
Vasculitis	1
Vertigo	1

The following adverse events occurred with an incidence of greater than or equal to 1% (N=112):headache: 10%; rhinitis: 9%; upper respiratory tract infection: 8%; sinusitis, injury: 7%; diarrhea,dyspepsia, flatulence, abdominal pain, dizziness, rash: 4%; cystitis, urinary tract infection, liver function abnormality, myalgia, nausea: 3%; appetite increased, constipation, gastritis, gastroenteritis, pharyngitis, asthenia, fever, pain, tremor, herpes zoster, abnormal dreaming: 2%.

Adverse Events Reported in Fingernail Onychomycosis Clinical Trials

Patients in these trials were on a course regimen consisting of two 1-week treatment periods of 200 mg twice daily, separated by a 3-week period without drug.

The following adverse events led to temporary or permanent discontinuation of therapy.

Table 5: Clinical Trials of Onychomycosis of the Fingernail: Adverse Events Leading to Temporary or Permanent Discontinuation of Therapy

	Incidence (%) Itraconazole (N=37)
Rash/Pruritus	3
Hypertriglyceridemia	3

The following adverse events occurred with an incidence of greater than or equal to 1% (N=37): headache: 8%; pruritus, nausea, rhinitis: 5%; rash, bursitis, anxiety, depression, constipation, abdominal pain, dyspepsia, ulcerative stomatitis, gingivitis, hypertriglyceridemia, sinusitis, fatigue, malaise, pain, injury: 3%.

Adverse Events Reported from Other Clinical Trials

In addition, the following adverse drug reaction was reported in patients who participated in itraconazole capsules clinical trials: Hepatobiliary Disorders: hyperbilirubinemia.

The following is a list of additional adverse drug reactions associated with itraconazole that have been reported in clinical trials of itraconazole oral solution and itraconazole IV excluding the adverse reaction term "Injection site inflammation" which is specific to the injection route of administration:

Cardiac Disorders: cardiac failure, left ventricular failure, tachycardia;

General Disorders and Administration Site Conditions: face edema, chest pain, chills;

Hepatobiliary Disorders: hepatic failure, jaundice;

Investigations: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, blood urea increased, gamma-glutamyltransferase increased, urine analysis abnormal;

Metabolism and Nutrition Disorders: hyperglycemia, hyperkalemia, hypomagnesemia;

Psychiatric Disorders: confusional state;

Renal and Urinary Disorders: renal impairment;

Respiratory, Thoracic and Mediastinal Disorders: dysphonia, cough;

Skin and Subcutaneous Tissue Disorders: rash erythematous, hyperhidrosis;

Vascular Disorders: hypotension

Post-marketing Experience

Adverse drug reactions that have been first identified during post-marketing experience with itraconazole capsules (all formulations) are listed in the table below. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.

Table 6: Postmarketing Reports of Adverse Drug Reactions

Blood and Lymphatic System Disorders:	Leukopenia, neutropenia, thrombocytopenia	
Immune System Disorders:	Anaphylaxis; anaphylactic, anaphylactoid and	
	allergic reactions; serum sickness; angioneurotic	
	edema	
Nervous System Disorders:	Peripheral neuropathy, paresthesia, hypoesthesia,	
	tremor	
Eye Disorders:	Visual disturbances, including vision blurred and	
	diplopia	
Ear and Labyrinth Disorders:	Transient or permanent hearing loss	
Cardiac Disorders:	Congestive heart failure	
Respiratory, Thoracic and Mediastina	tinalPulmonary edema, dyspnea	
Disorders:		
Gastrointestinal Disorders:	Pancreatitis, dysgeusia	
Hepatobiliary Disorders:	Serious hepatotoxicity (including some cases of fatal	
	acute liver failure), hepatitis	
Skin and Subcutaneous Tissue Disorders:	Toxic epidermal necrolysis, Stevens-Johnson	
	syndrome, acute generalized exanthematous	
	pustulosis, exfoliative dermatitis, leukocytoclastic	
	vasculitis, erythema multiforme, alopecia,	
	photosensitivity, urticaria	
Musculoskeletal and Connective Tissue	Arthralgia	
Disorders:		
Renal and Urinary Disorders:	Urinary incontinence, pollakiuria	
Reproductive System and Breast Disorders:	Erectile dysfunction	
General Disorders and Administration Site	Peripheral edema	
Conditions:		
Investigations:	Blood creatine phosphokinase increased	

There is limited information on the use of itraconazole capsules during pregnancy. Cases of congenital abnormalities including skeletal, genitourinary tract, cardiovascular and ophthalmic malformations as well as chromosomal and multiple malformations have been reported during post-marketing experience. A causal relationship with itraconazole capsules has not been established. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS: Drug Interactions for more information.)

OVERDOSAGE

Itraconazole is not removed by dialysis. In the event of accidental overdosage,

supportive measures should be employed. Contact a certified poison control center for the most up to date information on the management of itraconazole capsules overdosage (1-800-222-1222 or www.poison.org).

In general, adverse events reported with overdose have been consistent with adverse drug reactions already listed in this package insert for itraconazole. (See ADVERSE REACTIONS.)

DOSAGE AND ADMINISTRATION

Itraconazole capsules should be taken with a full meal to ensure maximal absorption. Itraconazole capsules must be swallowed whole.

Itraconazole capsules is a different preparation than itraconazole oral solution and should not be used interchangeably.

Treatment of Blastomycosis and Histoplasmosis:

The recommended dose is 200 mg once daily (2 capsules). If there is no obvious improvement, or there is evidence of progressive fungal disease, the dose should be increased in 100-mg increments to a maximum of 400 mg daily. Doses above 200 mg/day should be given in two divided doses.

Treatment of Aspergillosis:

A daily dose of 200 to 400 mg is recommended.

Treatment in Life-Threatening Situations:

In life-threatening situations, a loading dose should be used. Although clinical studies did not provide for a loading dose, it is recommended, based on pharmacokinetic data, that a loading dose of 200 mg (2 capsules) three times daily (600 mg/day) be given for the first 3 days of treatment.

Treatment should be continued for a minimum of three months and until clinical parameters and laboratory tests indicate that the active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection.

Itraconazole capsules and itraconazole oral solution should not be used interchangeably. Only the oral solution has been demonstrated effective for oral and/or esophageal candidiasis.

Treatment of Onychomycosis:

Toenails with or without fingernail involvement: The recommended dose is 200 mg (2 capsules) once daily for 12 consecutive weeks.

Treatment of Onychomycosis:

Fingernails only: The recommended dosing regimen is 2 treatment courses, each consisting of 200 mg (2 capsules) b.i.d. (400 mg/day) for 1 week. The courses are separated by a 3-week period without itraconazole capsules.

Use in Patients with Renal Impairment:

Limited data are available on the use of oral itraconazole in patients with renal impairment. Caution should be exercised when this drug is administered in this patient population. (See CLINICAL PHARMACOLOGY: Special Populations and PRECAUTIONS.)

Use in Patients with Hepatic Impairment:

Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population. (See CLINICAL PHARMACOLOGY: Special Populations, WARNINGS, and PRECAUTIONS.)

HOW SUPPLIED

Itraconazole capsules are available containing 100 mg of itraconazole USP, with a blue opaque cap and pink transparent body hard gelatin capsule imprinted with "ITR" on cap and "100" on body in white ink. The capsules are supplied in unit-dose blister packs of 3 \times 10 capsules (NDC 67877-454-84), bottles of 30 capsules (NDC 67877-454-30),bottle of 90 capsules (NDC 67877-454-90), bottle of 500 capsules (NDC 67877-454-05).

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture. Keep out of reach of children.

Manufactured by:

Alkem Laboratories Ltd., INDIA.

INDIA.

Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054

Revised: January, 2023

PATIENT INFORMATION

Itraconazole Capsules

(IT-ra-KON-a-zole)

Read this Patient Information that comes with itraconazole capsules before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.

What is the most important information I should know about itraconazole capsules? Itraconazole capsules can cause serious side effects, including:

- 1. Heart failure. Do not take itraconazole capsules if you have had heart failure, including congestive heart failure. Stop taking itraconazole capsules and call your healthcare provider right away if you have any of these symptoms of congestive heart failure:
 - shortness of breath
 - (phlegm)
- coughing up white or pink mucus
- swelling of your feet, ankles or legs fast heartbeat
- sudden weight gain • waking up at night more than normal for
- you
- increased tiredness
- 2. Heart problems and other serious medical problems. Serious medical problems that affect the heart and other parts of your body can happen if you take itraconazole capsules with certain other medicines. Do not take itraconazole capsules if you also take the following medicines:

 methadone 	 methylergometrine 	 ranolazine
 disopyramide 	(methylergonovine)	 eplerenone
• dofetilide	 irinotecan 	 cisapride
 dronedarone 	 lurasidone 	 naloxegol
• quinidine	 oral midazolam 	 lomitapide
 isavuconazole 	• pimozide	 lovastatin
 ergot alkaloids (such as 	• triazolam	 simvastatin
dihydroergotamine,	 felodipine 	 avanafil
ergometrine ergonovine)	 nisoldipine 	 ticagrelor
• ergotamine	• ivabradine	• venetoclax (see

below)

Do not take itraconazole capsules with venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma when you first start treatment with venetoclax or with increasing doses of venetoclax.

This is not a complete list of medicines that can interact with itraconazole capsules. Itraconazole capsules may affect the way other medicines work, and other medicines may affect how itraconazole capsules works. You can ask your pharmacist for a list of medicines that interact with itraconazole capsules.

Before you start taking itraconazole capsules, tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Before you start any new medicine, ask your healthcare provider or pharmacist if it is safe to take it with itraconazole capsules.

3. Liver problems. Itraconazole capsules can cause serious liver problems which may be severe and lead to death. Stop taking itraconazole capsules and call your healthcare provider right away if you have any of these symptoms of liver problems:

• tiredness	• your skin or the white part of your
 loss of appetite for several days or longer 	eyes turn yellow (jaundice)
nausea or vomiting	 light-colored stools (bowel movement)
dark or "tea-colored" urine	

For more information about side effects, see "What are the possible side effects of itraconazole capsules?"

What is itraconazole capsules?

- Itraconazole capsules is a prescription medicine used to treat the following fungal infections of the toenails, fingernails and other parts of the body: blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- It is not known if itraconazole capsules is safe and effective in children.

Do not take itraconazole capsules if you:

- have or have had heart failure, including congestive heart failure.
- take certain medicines. See "What is the most important information I should know about itraconazole capsules?"
- are pregnant or plan to become pregnant. Itraconazole capsules can harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking itraconazole capsules. Females who are able to become pregnant must use effective forms of birth control during treatment and for 2 months after stopping treatment with itraconazole capsules.
- are allergic to itraconazole or any of the ingredients in itraconazole capsules. See the end of this Patient Information leaflet for a complete list of ingredients in itraconazole capsules.

Before taking itraconazole capsules, tell your healthcare provider about all of your medical conditions, including if you:

- have heart problems.
- have liver problems.
- have kidney problems.
- have a weakened immune system (immunocompromised).
- have lung problems including cystic fibrosis.
- are breastfeeding or plan to breastfeed. Itraconazole can pass into your breast milk. You and your healthcare provider should decide if you will take itraconazole capsules or breastfeed.

Taking itraconazole capsules with certain medicines may affect each other. Taking itraconazole capsules with other medicines can cause serious side effects.

How should I take itraconazole capsules?

- Take itraconazole capsules exactly as prescribed by your healthcare provider. Your healthcare provider will tell you how much itraconazole capsules to take and when to take it.
- You will receive itraconazole capsules in a blister pack, bottle or PulsePak. Your healthcare provider will decide the type of itraconazole capsules that is right for you.
- Take itraconazole capsules with a full meal.
- · Swallow itraconazole capsules whole.
- You should not take itraconazole capsules oral solution instead of itraconazole capsules, because they will not work the same way.
- If you take too much itraconazole capsules, call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking itraconazole capsules?

Itraconazole capsules can cause dizziness and vision problems. Do not drive or operate machinery until you know how itraconazole capsules affects you.

What are the possible side effects of itraconazole capsules?

Itraconazole capsules may cause serious side effects, including:

- See "What is the most important information I should know about itraconazole capsules?"
- Nerve problems (neuropathy). Call your healthcare provider right away if you
 have tingling or numbness in your hands or feet. Your healthcare provider may stop
 your treatment with itraconazole capsules if you have nerve problems.
- **Hearing loss.** Hearing loss can happen for a short time or permanently in some people who take itraconazole capsules. Stop taking itraconazole capsules and call your healthcare provider right away if you have any changes in your hearing.

The most common side effects of itraconazole capsules include: headache, rash, and digestive system problems (such as nausea and vomiting). Additional possible side effects include upset stomach, vomiting, constipation, fever, inflammation of the pancreas, menstrual disorder, erectile dysfunction, dizziness, muscle pain, painful joints, unpleasant taste, or hair loss.

These are not all the possible side effects of itraconazole capsules.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store itraconazole capsules?

- Store itraconazole capsules at room temperature between 20° to 25°C (68° to 77°F)
- Keep itraconazole capsules dry and away from light.

Keep itraconazole capsules and all medicines out of the reach of children.

General information about the safe and effective use of itraconazole

capsules.

Medicines are sometimes prescribed for purposes other than those listed in a Patient

Information leaflet. Do not use itraconazole capsules for a condition for which it was not prescribed. Do not give itraconazole capsules to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your doctor or pharmacist for information about itraconazole capsules that is written for health professionals.

What are the ingredients in itraconazole capsules?

Active ingredients: itraconazole

Inactive ingredients: hard gelatin capsule, hypromellose, poloxamer 188, ethanol absolute, methylene chloride, polyethylene glycol 20000, talc, colloidal silicon dioxide, SLS, titanium dioxide, FD&C blue 1, FD&C red 40, FD & C red 3 and white ink (containing: shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, titanium dioxide and potassium hydroxide).

Manufactured by:

Alkem Laboratories Ltd., INDIA.

Distributed by:

Ascend Laboratories, LLC Parsippany, NJ 07054

For more information call 1-877-272-7901.

This Patient Information has been approved by the U.S. Food and Drug Administration

Revised: January, 2023

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 67877-454-30 ITRACONAZOLE CAPSULES 100 mg 30 Capsules Rx Only



NDC 67877-454-84 ITRACONAZOLE CAPSULES 100 mg 30(3 x 10)Unit Dose Capsules Rx Only



Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	ltem Co	de (Source)	NDC:67877-454	
Route of Administration	ORAL				
Active Ingredient/Activ	e Moiety				
Ing	gredient Name		Basis of Streng	th Strengt	
ITRACONAZOLE (UNII: 304NUG	5GF4) (ITRACONAZOLE - UNII:304NUC	5GF4)	ITRACONAZOLE	100 mg	
Inactive Ingredients					
		Strength			
SUCROSE (UNII: C151H8M554)					
HYPROMELLOSE 2910 (5 MPA	.S) (UNII: R75537T0T4)				
POLOXAMER 188 (UNII: LQA7B	5G8JG)				
ALCOHOL (UNII: 3K9958V90M)					
METHYLENE CHLORIDE (UNII:	588X2YUY0A)				
POLYETHYLENE GLYCOL 2000	00 (UNII: 5WKN5KL2O8)				
TALC (UNII: 7SEV7J4R1U)					
SILICON DIOXIDE (UNII: ETJ7Z6					
GELATIN, UNSPECIFIED (UNII:					
TITANIUM DIOXIDE (UNII: 15FIX					
SODIUM LAURYL SULFATE (UN					
FD&C BLUE NO. 1 (UNII: H3R47					
FD&C RED NO. 40 (UNII: WZB9					
FD&C RED NO. 3 (UNII: PN2ZH	SLOQY)				
SHELLAC (UNII: 46N107B710) ISOPROPYL ALCOHOL (UNII: NI	220416202)				
BUTYL ALCOHOL (UNII: 8PJ61P6 PROPYLENE GLYCOL (UNII: 6D0					
	22(10,13)				
AMMONIA (UNII: 5138Q19F1X) POTASSIUM HYDROXIDE (UNII:					

PI	oduct Cha	racteristics				
Color BLUE (Blue Opaque) , PINK (Pink transparent)				Score		no score
Sh	nape CAPSULE Size				21mm	
Fla	avor		Imprint Code			ITR;100
Co	ntains					
Pa	ackaging					
#	ltem Code	Package Description	Marketing Start Date		Marketing End Date	
	NDC:67877- 454-30	30 in 1 BOTTLE; Type 0: Not a Combination Product	12/06/2017			
	NDC:67877- 454-90	90 in 1 BOTTLE; Type 0: Not a Combination Product	12/06/2017			
	NDC:67877- 454-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	12/06/2017			
	NDC:67877- 454-84	3 in 1 CARTON	12/06/2017			
	NDC:67877- 454-33	10 in 1 BLISTER PACK; Type 0: Not a Combination Product				
M	arketing	Information				
	Marketing Category	Application Number or Monograph Citation		ting Start Date		eting End Date
	DA	ANDA208591	06/12/202	17		

Labeler - Ascend Laboratories, LLC (141250469)

Establishment

Name	Address	ID/FEI	Business Operations
Alkem Laboratories Limited		915628612	MANUFACTURE(67877-454)

Revised: 7/2023

Ascend Laboratories, LLC